Analysis of influencing factors of systemic immune-inflammatory index of pancreatic cancer and its correlation with clinical features
10.3760/cma.j.cn113884-20231207-00158
- VernacularTitle:胰腺癌患者全身免疫炎症指数影响因素分析及其与临床特征的相关性
- Author:
Yutong ZHOU
1
;
Xun RAN
;
Min HAN
Author Information
1. 贵州医科大学研究生院，贵阳 550003
- Keywords:
Pancreatic neoplasms;
Systemic immune-inflammatory index;
Influencing factors
- From:
Chinese Journal of Hepatobiliary Surgery
2024;30(5):370-374
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the relationship between systemic immune-inflammatory index (SII) and clinical characteristics of pancreatic cancer patients and the factors influencing SII.Methods:To retrospectively analyze the data of 98 pancreatic cancer patients with R 0 resection in the Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical University, from January 2018 to January 2023, of whom 54 were male and 44 were female at the age of (59.2±10.7) years. All patients were divided into the high SII group ( n=49) and the low SII group ( n=49) based on the median SII of 668. Preoperative albumin, proportion of tumor located in the head of the pancreas, preoperative total bilirubin, and length of hospitalization were compared between the two groups. The correlation between SII and clinical features was analyzed. The SII influencing factors of pancreatic cancer patients were analyzed by linear regression with univariate and multivariate analysis. Results:The preoperative albumin of pancreatic cancer patients in the high SII group was lower than that of the low SII group, while the proportion of tumors located in the head of the pancreas, the preoperative total bilirubin, and the length of hospital stay were higher than that of the low SII group, and the differences were all statistically significant (all P<0.05). Correlation analysis showed a negative correlation between preoperative albumin and SII ( r=-0.28, P=0.050), while a positive correlation between preoperative total bilirubin and SII ( r=0.36, P<0.001), as well as between hospitalization time and SII ( r=0.28, P=0.050). The SII of patients with tumors located in the head of the pancreas ( n=81) and the tail of the pancreatic body ( n=17) were 734 (418, 1 241) and 431 (276, 613), respectively, and the SII of patients who survived ( n=92) and died ( n=4) at the time of discharge were 628 (383, 1 113) and 1 283 (1 176, 1 507), respectively, and the differences in SII of patients with different tumor locations and different discharge status were all significant. The SII of the patients were compared, and the differences were statistically significant ( Z=-2.51, 2.05, P=0.012, 0.038). Screening variables in the univariate linear regression model showed that admission total bilirubin, tumor volume, and preoperative albumin were associated with SII levels (all P<0.05). When the above variables were included in the multivariate linear regression, the higher the preoperative total bilirubin ( β=2.74, 95% CI: 1.48-4.00, P<0.001) as well as the larger the tumor volume ( β=2.34, 95% CI: 1.04-3.63, P<0.001) in pancreatic cancer patients, the higher the value of SII. Conclusions:SII in pancreatic cancer patients was associated with preoperative albumin, tumor location, preoperative total bilirubin, length of hospital stay, and survival or death at discharge. Preoperative total bilirubin and tumor volume were influential factors of SII in patients with pancreatic cancer.
